In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Knoll and Tularik to develop obesity drugs

Executive Summary

Tularik Inc. (gene expression) entered a five-year collaboration with BASF AG's subsidiary Knoll AG (pharmaceuticals) in the area of obesity to discover and develop drugs that act on novel regulatory targets in energy metabolism pathways.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register